Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 80 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand
Sheep,
Cattle
Granted
New
Zealand
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle
Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle
Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig
Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Press Release

Taking the pain out of lamb marking: Tri–Solfen® approved for extended use in all sheep breeds

October 5, 2016

In a ground breaking new development for farmers, and for animal welfare – the Australian Veterinarian Medicine regulator (APVMA) has now extended the approved use of Tri-Solfen® anaesthetic to include the alleviation of pain in lambs, from all breeds, undergoing castration and tail docking.

Already approved and widely used to alleviate pain in lambs undergoing mulesing, Tri-Solfen® has a unique 3-way action designed to numb the wound, minimise bleeding and protect against infection. Scientific trials have demonstrated pain alleviation for up to 24 hours, and improved wound healing.

To date, 60 million lambs have been treated with Tri-Solfen®, with the product available to be purchased, over the counter, from your local veterinarian or rural retailers.

On-going trials conducted by Sydney University Veterinary School, confirmed that Tri-Solfen® is also effective in alleviating pain, post castration and tail docking in lambs.  The APVMA has now approved the product for these uses.

“It is a win for farmers, a win for lambs, a win for animal welfare – and a win for the Australian sheep and wool industry”, says Allan Giffard, Managing Director of Animal Ethics.  It provides a practical solution for farmers to alleviate the pain associated with these husbandry procedures, all three of which are relied on for important animal health and management reasons. This in turn may improve mothering-up and minimise set-back, whilst also addressing consumer concerns regarding welfare.”

“Farm animals experience pain in the same way as dogs, cats and other companion animals. They deserve the same respect and effort to develop safe, affordable and effective pain relief and wound care, that is practical for farmers to use.  Tri-Solfen® is the first product to successfully address this important need.”

It is currently estimated that 70 % of lambs undergoing mulesing each year, receive Tri-Solfen®.  Many, or most of these lambs, undergo surgical castration and/or tail docking at the same time.  The approval for the extension of use means that Tri-Solfen® may now be used to alleviate pain associated with all 3 wounds, at the same time. It may now also be used on all breeds of sheep.  An estimated 20 million sheep are castrated, and 30 million are tail docked, each year.

­– Ends­ –

About Medical Ethics

Medical Ethics is a commercial and development stage company focused on pain mitigation in wounds for humans and animals.

Through our proven patent protected platform technology, we have identified a transformational way of mitigating pain and minimising suffering associated with wounds.

About Tri-Solfen®

Tri-Solfen® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improves wound healing. Tri-Solfen® contains two proven topical local anaesthetics; fast-acting Lignocaine for immediate pain relief and long-acting Bupivacaine for prolonged post-operative pain relief. Adrenaline is included for its ability to reduce the shock and stress of blood loss, whilst prolonging the anaesthetic action. Tri-Solfen® also contains Cetrimide; an antiseptic widely used to cleanse skin and wounds and provides protection from bacterial contamination.

Further information

Medical Ethics:

Allan Giffard, Managing Director
Charles Olsson, Marketing Director
+61 419 362 286

FTI Consulting:

Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000